Tamar Peretz

Tamar Peretz

Auto-generated profile, based on publicly available information

Tamar Peretz

Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
EHEmma Hajaj
Emma Hajaj
EZElad Zisman
Elad Zisman
STShay Tzaban
Shay Tzaban
SMSharon Merims
Sharon Merims
JCJonathan Cohen
Jonathan Cohen
MLMichal Lotem
Michal Lotem
SLAMF6 is a homotypic receptor of the Ig-superfamily associated with progenitor-exhausted T cells. Here we show that in humans, SLAMF6 has three splice isoforms involving its V-domain. Although the canonical receptor inhibited T-cell activation through SAP recruitment, the short isoform SLAMF6Δ17–65 had a strong agonistic effect. The costimulatory action depended on protein phosphatase SHP1 and led to a cytotoxic molecular profile mediated by the expression of TBX21 and RUNX3. Patients treated with immune checkpoint blockade showed a shift toward SLAMF6Δ17–65 in peripheral blood T cells. We developed splice-switching antisense oligonucleotides (ASO) designed to target the relevant SLAMF6 splice junction. Our ASOs enhanced SLAMF6Δ17–65 expression in human tumor-infiltrating lymphocytes and improved their capacity to inhibit human melanoma in mice. The yin-yang relationship of SLAMF6 splice isoforms may represent a balancing mechanism that could be exploited to improve cancer immunotherapy.

23 October 2009 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
Yael GoldbergYael Goldberg
Yael Goldberg
RPRinnat M. Porat
Rinnat M. Porat
IKInbal Kedar
Inbal Kedar
CSChen Shochat
Chen Shochat
DGDaliah Galinsky
Daliah Galinsky
TPTamar Peretz
Tamar Peretz

12 November 2021 in ESMO Open
Verified
Journal Article
Open access
MCM. Condorelli
M. Condorelli
MBMarco Bruzzone
Marco Bruzzone
MCMarcello Ceppi
Marcello Ceppi
AFAlberta Ferrari
Alberta Ferrari
AGAlbert Grinshpun
Albert Grinshpun
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
Knowledge is growing on the safety of assisted reproductive techniques (ART) in cancer survivors. No data exist, however, for the specific population of breast cancer patients harboring germline BRCA1/2 pathogenic variants. This is a multicenter retrospective cohort study across 30 centers worldwide including women diagnosed at ≤40 years with stage I-III breast cancer, between January 2000 and December 2012, harboring known germline BRCA1/2 pathogenic variants. Patients included in this analysis had a post-treatment pregnancy either achieved through use of ART (ART group) or naturally (non-ART group). ART procedures included ovulation induction, ovarian stimulation for in vitro fertilization or intracytoplasmic sperm injection, and embryo transfer under hormonal replacement therapy. Among the 1424 patients registered in the study, 168 were eligible for inclusion in the present analysis, of whom 22 were in the ART group and 146 in the non-ART group. Survivors in the ART group conceived at an older age compared with those in the non-ART group (median age: 39.7 versus 35.4 years, respectively). Women in the ART group experienced more delivery complications compared with those in the non-ART group (22.1% versus 4.1%, respectively). No other apparent differences in obstetrical outcomes were observed between cohorts. The median follow-up from pregnancy was 3.4 years (range: 0.8-8.6 years) in the ART group and 5.0 years (range: 0.8-17.6 years) in the non-ART group. Two patients (9.1%) in the ART group experienced a disease-free survival event (specifically, a locoregional recurrence) compared with 40 patients (27.4%) in the non-ART group. In the ART group, no patients deceased compared with 10 patients (6.9%) in the non-ART group. This study provides encouraging safety data on the use of ART in breast cancer survivors harboring germline pathogenic variants in BRCA1/2, when natural conception fails or when they opt for ART in order to carry out preimplantation genetic testing.

15 February 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
LVLeonid Visochek
Leonid Visochek
ACAsher Castiel
Asher Castiel
LMLeonid Mittelman
Leonid Mittelman
MEMichael Elkin
Michael Elkin
DADikla Atias
Dikla Atias
Malka Cohen-ArmonMalka Cohen-Armon
Malka Cohen-Armon
Exclusive destruction of mitotic spindles in human cancer cells

11 February 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RURonny Uzana
Ronny Uzana
GEGalit Eisenberg
Galit Eisenberg
SMSharon Merims
Sharon Merims
SFShoshana Frankenburg
Shoshana Frankenburg
APAviad Pato
Aviad Pato
MLMichal Lotem
Michal Lotem
Trogocytosis is a contact-dependent unidirectional transfer of membrane fragments between immune effector cells and their targets, initially detected in T cells following interaction with professional antigen presenting cells (APC). Previously, we have demonstrated that trogocytosis also takes place between melanoma-specific cytotoxic T lymphocytes (CTLs) and their cognate tumors. In the present study, we took this finding a step further, focusing on the ability of melanoma membrane-imprinted CD8+ T cells to act as APCs (CD8+T-APCs). We demonstrate that, following trogocytosis, CD8+T-APCs directly present a variety of melanoma derived peptides to fraternal T cells with the same TCR specificity or to T cells with different TCRs. The resulting T cell-T cell immune synapse leads to (1) Activation of effector CTLs, as determined by proliferation, cytokine secretion and degranulation; (2) Fratricide (killing) of CD8+T-APCs by the activated CTLs. Thus, trogocytosis enables cross-reactivity among CD8+ T cells with interchanging roles of effectors and APCs. This dual function of tumor-reactive CTLs may hint at their ability to amplify or restrict reactivity against the tumor and participate in modulation of the anti-cancer immune response.

28 November 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CMChen Makranz
Chen Makranz
ALAsael Lubotzky
Asael Lubotzky
HZHai Zemmour
Hai Zemmour
RSRuth Shemer
Ruth Shemer
BGBenjamin Glaser
Benjamin Glaser
AZAviad Zick
Aviad Zick
Background: Radiotherapy has an important role in the treatment of brain metastases but carries risk of short and/or long-term toxicity, termed radiation-induced brain injury (RBI). As the diagnosis of RBI is crucial for correct patient management, there is an unmet need for reliable biomarkers for RBI. The aim of this proof-of concept study is to determine the utility of brain-derived circulating free DNA (BncfDNA), identified by specific methylation patterns for neurons, astrocytes, and oligodendrocytes, as biomarkers brain injury induced by radiotherapy. Methods: Twenty-four patients with brain metastases were monitored clinically and radiologically before, during and after brain radiotherapy, and blood for BncfDNA analysis (98 samples) was concurrently collected. Sixteen patients were treated with whole brain radiotherapy and eight patients with stereotactic radiosurgery. Results: During follow-up nine RBI events were detected, and all correlated with significant increase in BncfDNA levels compared to baseline. Additionally, resolution of RBI correlated with a decrease in BncfDNA. Changes in BncfDNA were independent of tumor response. Conclusions: Elevated BncfDNA levels reflects brain cell injury incurred by radiotherapy. further research is needed to establish BncfDNA as a novel plasma-based biomarker for brain injury induced by radiotherapy.